Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID L OLIVER

Allopathic & Osteopathic Physicians Family Medicine

NPI
1164404455
CMS profile
623992
Location
OCALA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$282.42

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $282.42 6

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Lilly USA, LLC $98.06 3
IRONWOOD PHARMACEUTICALS, INC $97.87 1
Esperion Therapeutics, Inc. $71.44 1
Smith+Nephew, Inc. $15.05 1

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID L OLIVER

NPI 1164404455 · CMS profile ID 623992

Allopathic & Osteopathic Physicians / Family Medicine

OCALA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1164404455?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID L OLIVER, NPI 1164404455, CMS profile ID 623992. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1164404455?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). DAVID L OLIVER, NPI 1164404455, CMS profile ID 623992. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1164404455?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
DAVID L OLIVER, NPI 1164404455, CMS profile ID 623992, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1164404455?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $282.42 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Esperion Therapeutics, Inc. $71.4410/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737230045 CMS
Lilly USA, LLC $76.6103/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728385367 CMS
Lilly USA, LLC $5.3603/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728394699 CMS
Lilly USA, LLC $16.0903/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728405821 CMS
Smith+Nephew, Inc. $15.0502/07/2020 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 750123143 CMS
IRONWOOD PHARMACEUTICALS, INC $97.8702/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749780691 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $405.23 5
PY2020 $282.42 6
PY2021 $509.12 6
PY2022 $770.26 8
PY2023 $290.27 6
PY2024 $2,305.91 23
PY2025 $352.28 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,288,478.03 35
PY2024 Recipient $48,730.50 2
PY2024 Principal investigator $760,191.54 106
PY2023 Recipient $795.01 2
PY2023 Principal investigator $798,688.88 48
PY2022 Recipient $274.00 1
PY2022 Principal investigator $738,187.49 166
PY2021 Principal investigator $437,882.52 38
PY2020 Recipient $193,202.48 6
PY2020 Principal investigator $298,634.23 42
PY2019 Principal investigator $211,648.73 76

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

108 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novo Nordisk AS $1,000.00 12/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096685794
Principal investigator 1 Novo Nordisk AS $1,306.89 12/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096694685
Principal investigator 1 Tolmar, Inc. $510.30 12/05/2024 Non-covered Recipient Entity
RENSTAR LLC
A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO for 12 Months No dispute reported 06/30/2026 1141549253
Principal investigator 1 Tolmar, Inc. $2,107.40 12/05/2024 Non-covered Recipient Entity
RENSTAR LLC
A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO for 12 Months No dispute reported 06/30/2026 1141549255
Principal investigator 1 Novo Nordisk AS $2,072.15 11/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096626003
Principal investigator 1 Novo Nordisk AS $219.60 10/31/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096632288
Principal investigator 1 Novo Nordisk AS $2,278.15 10/31/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096670932
Principal investigator 1 Novo Nordisk AS $219.60 09/30/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096695540
Recipient Eli Lilly and Company $41,512.50 09/24/2024 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1137346812
Recipient Eli Lilly and Company $7,218.00 09/24/2024 Covered Recipient Physician A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) No dispute reported 06/30/2026 1137347178
Principal investigator 1 Novo Nordisk AS $1,604.12 09/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096643392
Principal investigator 1 Tolmar, Inc. $1,872.34 09/12/2024 Non-covered Recipient Entity
RENSTAR LLC
A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO for 12 Months No dispute reported 06/30/2026 1141549261
Principal investigator 1 Novo Nordisk AS $297.00 09/10/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096659619
Principal investigator 1 Novo Nordisk AS $1,898.46 08/23/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096697164
Principal investigator 1 Novo Nordisk AS $1,518.77 07/22/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096690342
Principal investigator 1 Novo Nordisk AS $1,501.16 06/21/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096691922
Principal investigator 1 Tolmar, Inc. $3,000.00 06/06/2024 Non-covered Recipient Entity
RENSTAR LLC
A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO for 12 Months No dispute reported 06/30/2026 1141549257
Principal investigator 1 Tolmar, Inc. $7,500.00 06/06/2024 Non-covered Recipient Entity
RENSTAR LLC
A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO for 12 Months No dispute reported 06/30/2026 1141549259
Principal investigator 1 Tolmar, Inc. $2,000.00 06/06/2024 Non-covered Recipient Entity
RENSTAR LLC
A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO for 12 Months No dispute reported 06/30/2026 1141549263
Principal investigator 1 Novo Nordisk AS $2,255.87 05/31/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096675106
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096626699
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096628391
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096628627
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096629876
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096629920
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096630286
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096632166
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096636182
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096637581
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096638157
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096638646
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096640094
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096641726
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096643803
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096645344
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096647463
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096652533
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096653096
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096653528
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096656549
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096657608
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096660176
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096660521
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096663904
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096667526
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096667530
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096668322
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096668518
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096668933
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096670077
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096672352
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096677388
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096680894
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096682028
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096682528
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096684083
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096685664
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096685716
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096685759
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096685820
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096687342
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096690346
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096691524
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096693106
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096693529
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096695460
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096696633
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096698732
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096699223
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096699792
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096699828
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096700276
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096701227
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096702163
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096705444
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096707334
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096710902
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096711526
Principal investigator 1 Novo Nordisk AS $11.38 05/20/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096711883
Principal investigator 1 Novo Nordisk AS $1,798.20 05/17/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096686309
Principal investigator 1 Novo Nordisk AS $19.95 05/10/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096635499
Principal investigator 1 Novo Nordisk AS $19.95 05/10/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096636715
Principal investigator 1 Novo Nordisk AS $19.95 05/10/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096642760
Principal investigator 1 Novo Nordisk AS $19.95 05/10/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096652565
Principal investigator 1 Novo Nordisk AS $19.95 05/10/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096654678
Principal investigator 1 Novo Nordisk AS $19.95 05/10/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096656236
Principal investigator 1 Novo Nordisk AS $19.95 05/10/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096675126
Principal investigator 1 Novo Nordisk AS $19.95 05/10/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096678451
Principal investigator 1 Novo Nordisk AS $19.95 05/10/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096688374
Principal investigator 1 Novo Nordisk AS $19.95 05/10/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096688814
Principal investigator 1 Novo Nordisk AS $19.95 05/10/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096691410
Principal investigator 1 Novo Nordisk AS $19.95 05/10/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096696694
Principal investigator 1 Novo Nordisk AS $19.95 05/10/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096699728
Principal investigator 1 Novo Nordisk AS $19.95 05/10/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096708334
Principal investigator 1 Novo Nordisk AS $2,720.92 04/30/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096709451
Principal investigator 1 Novo Nordisk AS $24.56 04/08/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096692483
Principal investigator 1 Eli Lilly and Company $160,686.00 04/01/2024 Non-covered Recipient Entity
RENSTAR INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1137365209
Principal investigator 1 Novo Nordisk AS $4,537.34 03/29/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096711438
Principal investigator 1 Eli Lilly and Company $5,371.35 03/04/2024 Non-covered Recipient Entity
RENSTAR INC
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 1137365331
Principal investigator 1 Eli Lilly and Company $666.78 03/01/2024 Non-covered Recipient Entity
RENSTAR INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1137365811
Principal investigator 1 Eli Lilly and Company $5,554.24 02/28/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1137366931
Principal investigator 1 Novo Nordisk AS $219.60 01/31/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096672942
Principal investigator 1 Novo Nordisk AS $219.60 01/31/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096672945
Principal investigator 1 Novo Nordisk AS $1,000.00 01/29/2024 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1096669504
Principal investigator 1 Eli Lilly and Company $1,273.84 01/16/2024 Non-covered Recipient Entity
RENSTAR INC
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) No dispute reported 06/30/2026 1137366257
Principal investigator 1 Eli Lilly and Company $1,941.58 01/04/2024 Non-covered Recipient Entity
RENSTAR INC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1137365809
Principal investigator 1 Eli Lilly and Company $111,238.00 01/02/2024 Non-covered Recipient Entity
RENSTAR INC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1137365807
Principal investigator 1 Eli Lilly and Company $428,827.00 01/02/2024 Non-covered Recipient Entity
RENSTAR INC
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) No dispute reported 06/30/2026 1137366253